| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fbff5d135287d37ddb9caa0de875c843 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-69 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-69 |
| filingDate |
2019-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94b347ad9e7f4dcffbcfa4f206f852a1 |
| publicationDate |
2020-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20200137707-A |
| titleOfInvention |
Novel sulfadiazinyl derivative compound and use thereof |
| abstract |
The present invention provides a novel sulfadiazine derivative compound, an optical isomer thereof, or a pharmaceutically acceptable salt thereof. The novel sulfadiazine derivative compound according to the present invention, its optical isomer or its pharmaceutically acceptable salt, inhibits CIAP (calf intestinal alkaline phosphatase) and inhibits active oxygen. It shows excellent effects in the prevention and treatment of intestinal diseases. |
| priorityDate |
2019-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |